Evaxion Biotech A/S ADR (EVAX) Stock Price, Quote & News

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 31 31 97 53

Website: evaxion.ai

Address:

Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark

Manwiththeplan Aug. 18 at 2:37 PM

$EVAX nice

0 · Reply

Manwiththeplan Aug. 15 at 5:01 PM

$EVAX - Milestonepayment on track for H2 2025 - 11/16 patients still in study. Most are doing 'extremely' well - multiple ongoing discussions about partnerships

0 · Reply

Manwiththeplan Aug. 15 at 4:47 PM

$EVAX https://youtu.be/NAHLGl9jcxY?si=Qpe_OrSSIbABSgsB

0 · Reply

MT25 Aug. 14 at 6:03 PM

$EVAX good update today ! Things on track👍💪

0 · Reply

Manwiththeplan Aug. 14 at 3:55 PM

$EVAX were there any good questions at the CC. I could not join.

1 · Reply

Lenni_D Aug. 14 at 11:40 AM

$EVAX https://investors.evaxion.ai/news-releases/news-release-details/evaxion-announces-business-update-and-second-quarter-2025

1 · Reply

Manwiththeplan Aug. 13 at 8:08 PM

$EVAX nice finish. I think there wont be any news tomorrow. News will come in october.

1 · Reply

Manwiththeplan Aug. 13 at 7:41 PM

$EVAX

0 · Reply

Manwiththeplan Aug. 13 at 7:18 PM

$EVAX

0 · Reply

Manwiththeplan Aug. 13 at 1:59 PM

$EVAX chartwise it should break 3 coming days

0 · Reply

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Jul 25, 2025, 9:00 AM EDT - 24 days ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 11, 2025, 8:00 AM EDT - 5 weeks ago

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 1, 2025, 8:30 AM EDT - 6 weeks ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jun 25, 2025, 8:00 AM EDT - 7 weeks ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 3, 2025, 9:15 AM EDT - 2 months ago

Evaxion receives grant funding to design new polio vaccine

May 27, 2025, 10:43 AM EDT - 2 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 7:30 AM EDT - 2 months ago

Evaxion announces business update and first quarter 2025 financial results

May 26, 2025, 8:47 AM EDT - 3 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 23, 2025, 8:00 AM EDT - 3 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 22, 2025, 8:00 AM EDT - 3 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Apr 28, 2025, 8:00 AM EDT - 4 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 10, 2025, 8:00 AM EDT - 4 months ago

Evaxion to present at World Vaccine Congress

Apr 1, 2025, 11:21 AM EDT - 4 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:00 AM EDT - 5 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 25, 2025, 4:30 PM EDT - 5 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Feb 25, 2025, 8:00 AM EST - 6 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Jan 31, 2025, 4:05 PM EST - 7 months ago

Evaxion announces closing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 7 months ago

Evaxion announces pricing of $10.8 million public offering

Jan 28, 2025, 8:15 AM EST - 7 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 14, 2025, 4:05 PM EST - 7 months ago

Evaxion announces completion of ADS ratio change

Jan 10, 2025, 8:00 AM EST - 7 months ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 8 months ago

Evaxion announces plan to implement ADS ratio change

Nov 12, 2024, 8:00 AM EST - 9 months ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Oct 31, 2024, 8:00 AM EDT - 10 months ago

Evaxion announces business update and third quarter 2024 financial results

Oct 28, 2024, 8:00 AM EDT - 10 months ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 9, 2024, 8:00 AM EDT - 11 months ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 3, 2024, 8:00 AM EDT - 11 months ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Sep 26, 2024, 10:53 AM EDT - 11 months ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Sep 26, 2024, 7:30 AM EDT - 11 months ago

Evaxion significantly expands vaccine development collaboration with MSD

Sep 19, 2024, 8:00 AM EDT - 11 months ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Aug 14, 2024, 11:43 AM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 7:27 AM EDT - 1 year ago

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Jul 3, 2024, 8:05 AM EDT - 1 year ago

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Jun 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Jun 17, 2024, 8:44 AM EDT - 1 year ago

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

May 28, 2024, 8:21 AM EDT - 1 year ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

May 23, 2024, 5:00 PM EDT - 1 year ago

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

May 10, 2024, 5:00 PM EDT - 1 year ago

Evaxion Receives Nasdaq Notification

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Apr 2, 2024, 2:10 PM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Evaxion Announces Business Update and Full Year 2023 Financial Results

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Feb 29, 2024, 7:30 AM EST - 1 year ago

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Feb 20, 2024, 7:30 AM EST - 1 year ago

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Manwiththeplan Aug. 18 at 2:37 PM

$EVAX nice

0 · Reply

Manwiththeplan Aug. 15 at 5:01 PM

$EVAX - Milestonepayment on track for H2 2025 - 11/16 patients still in study. Most are doing 'extremely' well - multiple ongoing discussions about partnerships

0 · Reply

Manwiththeplan Aug. 15 at 4:47 PM

$EVAX https://youtu.be/NAHLGl9jcxY?si=Qpe_OrSSIbABSgsB

0 · Reply

MT25 Aug. 14 at 6:03 PM

$EVAX good update today ! Things on track👍💪

0 · Reply

Manwiththeplan Aug. 14 at 3:55 PM

$EVAX were there any good questions at the CC. I could not join.

1 · Reply

Lenni_D Aug. 14 at 11:40 AM

$EVAX https://investors.evaxion.ai/news-releases/news-release-details/evaxion-announces-business-update-and-second-quarter-2025

1 · Reply

Manwiththeplan Aug. 13 at 8:08 PM

$EVAX nice finish. I think there wont be any news tomorrow. News will come in october.

1 · Reply

Manwiththeplan Aug. 13 at 7:41 PM

$EVAX

0 · Reply

Manwiththeplan Aug. 13 at 7:18 PM

$EVAX

0 · Reply

Manwiththeplan Aug. 13 at 1:59 PM

$EVAX chartwise it should break 3 coming days

0 · Reply

Kantus Aug. 13 at 1:16 PM

$EVAX

0 · Reply

MT25 Aug. 13 at 12:48 PM

$EVAX Insane AI platform. Target 25 in one year. 13+ for success with the vaccine the rest of the upside for the AI platform👍

0 · Reply

Espre Aug. 13 at 10:51 AM

$EVAX took a position, good luck tomorrow everyone 👍

0 · Reply

Manwiththeplan Aug. 12 at 5:25 PM

$EVAX last chance to load up

1 · Reply

Stmkr Aug. 12 at 1:03 PM

$EVAX I think $IOBT data are bullish for $EVAX as well and support potential of cancer vaccines to improve responses to anti-PD1

0 · Reply

Manwiththeplan Aug. 11 at 3:15 PM

$EVAX ihope some guidance 14th. Also some clearity about why CEO left and the search for new CEO

0 · Reply

Lenni_D Aug. 11 at 1:28 PM

$EVAX https://investors.evaxion.ai/news-releases/news-release-details/evaxion-announce-business-update-and-second-quarter-2025 Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

0 · Reply

Manwiththeplan Aug. 7 at 4:15 PM

$EVAX low market cap! Enough cash for > 1 year. Potential milestone payment of 10 million Phase 2 data in october (current CSO is really positive about it) CEO left in july and everyobe is really positive about him on his linked in Do not sell now. You can sell in october

0 · Reply

Manwiththeplan Aug. 7 at 4:03 PM

$EVAX 3 today would be nice

0 · Reply

_TechnicalSwing Aug. 6 at 10:38 PM

$EVAX Is there a confirmed ER Date?

1 · Reply

Lemuren Aug. 6 at 1:27 PM

$EVAX SLAPPYDOCK for life

0 · Reply

Manwiththeplan Aug. 4 at 1:47 PM

$EVAX 4 in august

0 · Reply

Market Cap	2.30M
Revenue (ttm)	3.34M
Net Income (ttm)	-10.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-316.47%
Debt to Equity Ratio	-4.95

Volume	57,600
Avg Vol	68,002
Day's Range	N/A - N/A
Shares Out	1.40M
Stochastic %K	76%
Beta	-0.24
Analysts	Strong Sell
Price Target	$13.25